On Biostatistics and Clinical Trials: Open-Label Extension (OLE) Study
Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III
Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
Understanding Clinical Trial Terminology: What is a Long-Term Extension or Open-Label Extension Study? - Concert Pharmaceuticals
Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram
Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram
FOURIER Open Label Extension – TIMI STUDY GROUP
Spotlight on Open-Label Extension Studies
Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study) - American Journal of Cardiology
FOURIER Open Label Extension – TIMI STUDY GROUP
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension | Clinical and Translational Allergy | Full
Study Design for PIONEER I and II, and Open-Label Extension | Download Scientific Diagram
Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA) - ACR Meeting Abstracts
Seguridad y eficacia a largo plazo del ácido bempedoico en pacientes con enfermedad cardiovascular aterosclerótica y/
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT - The Lancet Diabetes & Endocrinology
Efficacy | ULTOMIRIS® (ravulizumab-cwvz) | gMG
An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text
What is TEGSEDI® (inotersen)? | MOA, Safety & Study Design
An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis | Arthritis Research & Therapy | Full Text
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study - The Lancet Respiratory Medicine
Patient flow during the 24-week open-label extension (OLE). a Reasons... | Download Scientific Diagram
NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience® (Mazindol ER) in the Treatment of Narcolepsy - Wake Up Narcolepsy
Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
Schematic view of an open label extension to a randomized controlled... | Download Scientific Diagram
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism | Genetics in Medicine
Schematic view of an open label extension to a randomized controlled... | Download Scientific Diagram
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE) - The Lancet Respiratory Medicine
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases | Business Wire
